Humanin is unusual among research peptides: your own body makes it, and the instructions live inside your mitochondria. Mitochondria (the cell’s energy factories) carry their own small loop of DNA, and tucked inside it is the code for humanin — a short peptide of about 21 to 24 amino acids. It was one of the first "mitochondrial-derived peptides" ever identified, and it arrived with a dramatic origin story.
In plain terms: a natural peptide made by the cell’s power plants, discovered because it seemed to keep brain cells alive — fascinating biology, but studied almost entirely in dishes and rodents.
What it is
Most peptides in this space are foreign molecules. Humanin is not: it is encoded within mitochondrial DNA and produced by the body itself. That makes it part of a small, still-emerging class of signalling molecules (chemical messengers) that mitochondria send out to the rest of the cell and body.
It was discovered in 2001 by a Japanese group who were hunting for something that could protect neurons (brain cells) from Alzheimer’s-related damage. They screened a surviving piece of brain tissue and pulled out a gene that, on its own, stopped neurons dying from a range of Alzheimer’s-linked triggers — and named it humanin1.
How it is thought to work
Humanin behaves like a survival and stress-resistance signal. Reported actions from laboratory work include:
- Neuroprotection — in cell studies it blocked neuron death caused by mutant Alzheimer’s genes and by amyloid-beta, the protein fragment tied to the disease1.
- Metabolic signalling — in rodents, humanin acting through the brain improved insulin sensitivity (how well the body responds to insulin to control blood sugar)2.
- Cell protection and stress resistance — it engages survival pathways inside cells, part of why it is framed as a longevity signal3.
In plain terms: it reads like a "hang in there" message to stressed cells. Strong and repeatable in the lab — but lab is where nearly all of it lives.
It declines with age
One finding drives much of the longevity interest: humanin levels in the blood fall as we get older, in both humans and mice, and drop in several tissues in ageing rodents2. Restoring a youthful signal is the obvious question that follows — and in the lab, raising humanin activity did notable things (see below).
Pharmacokinetics and half-life
Natural humanin is short-lived in the bloodstream — like many small peptides, it is broken down quickly. Because of that, much of the research uses engineered, longer-lasting versions (analogs such as one called HNG) that resist breakdown and act more potently than the natural peptide2. Precise human half-life figures are not well established, which itself reflects how little human dosing work exists.
What the studies actually found
The interesting results are real — and, with one small human-relevant exception, they are from cells and rodents. Note the level in every row.
| Study (cited) | Model / level | Key result | Year |
|---|---|---|---|
| Hashimoto et al.1 | Cell culture (neurons) | Humanin nearly abolished neuron death from multiple Alzheimer’s triggers | 2001 |
| Muzumdar et al.2 | Rodent + human blood levels | Humanin improved insulin sensitivity in rats; blood levels shown to fall with age in humans and mice | 2009 |
| Yen et al.3 | Worm + mouse (review of models) | A humanin-like signal extended lifespan in C. elegans and tracked with healthspan measures | 2020 |
The pattern: consistent, genuinely interesting protective and metabolic signals — built from cell cultures, worms, and rodents. The one human thread is descriptive (measuring the peptide in blood), not a treatment trial.
The honest catch
This is the part to hold onto. Humanin has almost no controlled human efficacy data. Everything exciting — rescuing neurons, improving insulin response, extending lifespan — comes from preclinical models. That does not make it uninteresting; it makes it unproven in people. An animal result stated as if it were a human outcome would be a mistake.
Latest research
- Lifespan and healthspan framing (2020). Work from the Cohen group positioned humanin as a regulator of lifespan, showing lifespan extension in worms and linking the peptide to metabolic health across models3.
- The class is growing. Humanin is now seen as the flagship of a wider family of mitochondrial-derived peptides (others include MOTS-c and the SHLPs), and interest has shifted toward mapping what the whole family does.
- Human trials remain the missing piece. The biggest gap is unchanged: no controlled human efficacy trials, which keeps humanin firmly in the "promising but preclinical" column.
The short version
Humanin is a small peptide your own mitochondria encode, discovered in 2001 for its apparent power to keep neurons alive1. Cell and animal studies tie it to neuroprotection, better insulin sensitivity, and longevity, and its blood levels fall with age23. But the evidence is overwhelmingly preclinical, with essentially no controlled human trials — a research compound, not a medicine. Educational overview only. For context, see what are research peptides.